A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs DCR PHXC (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; First in man; Proof of concept
- 16 Oct 2017 According to a Dicerna Pharmaceuticals media release, the company has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The company plans to submit additional CTAs in other European countries later this year. Initial data from this trial is expected in 2018.
- 08 May 2017 This trial is expected to begin in the first quarter of 2018, according to a Dicerna Pharmaceuticals media release.
- 22 Nov 2016 New trial record